Ļć½¶ŹÓʵ

Ghulam Rehman Mohyuddin
( out of 139 reviews )

Ghulam Rehman Mohyuddin, MBBS

Languages spoken: English, Hindi, Pushto, Urdu

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City

  • Dr. Mohyuddin completed his medical training at the prestigious Aga Khan Ļć½¶ŹÓʵ in Pakistan. He completed his internal medicine residency at the Ļć½¶ŹÓʵ of Kansas where he developed a passion for medical education and treating hematological malignancies. He completed his fellowship at the Ļć½¶ŹÓʵ of Kansas, developing a clinical and research interest in multiple myeloma, drug repurposing, quality of scientific methods, end of life, cost-effective/evidence-based care and medical education. He enjoys the outdoors tremendously, and that drew him to life in Utah where he is currently an Assistant Professor at the Huntsman Cancer Institute with a focus on multiple myeloma. His clinical interests focus on the treatment of multiple myeloma and other plasma cell dyscrasias. His specific research interests include the design and quality of clinical trials in MM, medical education, high-value care, and risk adapted/personalized therapies for patients with plasma cell dycrasias. His work has been published in high impact medical journals and he has designed numerous innovative trials to further high-value care, and improve quality of life for patients with myeloma and its precursor conditions.

    Specialties

    Board Certification

    American Board of Internal Medicine (Dual Sub: Hematology and Medical Oncology)
    American Board of Internal Medicine (Internal Medicine)

    Patient Rating

    4.9 /5
    ( out of 139 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 19, 2024
    HUNTSMAN CANCER CENTER

    Dr Mohy is a very caring, concerned Dr. towards his patients.would highly recommend him and Huntsman to anyone needing treatment.

    September 12, 2024
    HUNTSMAN CANCER CENTER

    Dr. Mohy Ud Din is a physician with a caring approach that develops an intervention plan that is understandable to the patient.

    September 07, 2024
    HUNTSMAN CANCER CENTER

    Both were very good at looking for the real issues with my heath. I know I'm in good hands not just a number. Thank you!

    September 05, 2024
    HUNTSMAN CANCER CENTER

    One of the best doctors I have ever had. Has a good manner about him listen carefully , makes good informed decisions based on my needs.

    July 26, 2024
    HUNTSMAN CANCER CENTER

    I feel well cared for and listened to

    July 24, 2024
    HUNTSMAN CANCER CENTER

    Very very knowledgeable, and competent explained everything on my level. OUTSTANDING.

    July 03, 2024
    HUNTSMAN CANCER CENTER

    The doctor is always very kind and very professional. He conveys a sense of understanding of my needs and the best medical practices to apply to those knees. I enjoy my visits with the doctor.

    June 21, 2024
    HUNTSMAN CANCER CENTER

    Appreciate working with him, he is kind, and a good listner

    June 20, 2024
    HUNTSMAN CANCER CENTER

    I love Dr. Manny. He seems genuinely concerned for me and my health and is trying to help me as best he can.

    See More Patient Comments

  • Dr. Mohyuddin completed his medical training at the prestigious Aga Khan Ļć½¶ŹÓʵ in Pakistan. He completed his internal medicine residency at the Ļć½¶ŹÓʵ of Kansas where he developed a passion for medical education and treating hematological malignancies. He completed his fellowship at the Ļć½¶ŹÓʵ of Kansas, developing a clinical and research interest in multiple myeloma, drug repurposing, quality of scientific methods, end of life, cost-effective/evidence-based care and medical education. He enjoys the outdoors tremendously, and that drew him to life in Utah where he is currently an Assistant Professor at the Huntsman Cancer Institute with a focus on multiple myeloma. His clinical interests focus on the treatment of multiple myeloma and other plasma cell dyscrasias. His specific research interests include the design and quality of clinical trials in MM, medical education, high-value care, and risk adapted/personalized therapies for patients with plasma cell dycrasias. His work has been published in high impact medical journals and he has designed numerous innovative trials to further high-value care, and improve quality of life for patients with myeloma and its precursor conditions.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Dual Sub: Hematology and Medical Oncology)
    American Board of Internal Medicine (Internal Medicine)

    Education history

    Fellowship Hematology-Oncology - Ļć½¶ŹÓʵ of Kansas Medical Center Fellow
    Chief Resident Internal Medicine - Ļć½¶ŹÓʵ of Kansas Medical Center Chief Resident
    Residency Internal Medicine Categorical Residency - Ļć½¶ŹÓʵ of Kansas Medical Center Resident
    Professional Medical Medicine, Surgery - Aga Khan Ļć½¶ŹÓʵ, Medical College M.B.B.S.

    Selected Publications

    Journal Article

    1. Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, Sandhu I, McCurdy A, Facon T, Mateos MV, Mian H (2024). Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv, 8(23), 5993-6002. ()
    2. Mohyuddin GR, Guadamuz JS, Ascha MS, Chiu BC, Patel PR, Sweiss K, Rohrer R, Sborov D, Calip GS (2024). Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study. Blood Adv, 8(21), 5539-5541. ()
    3. Kapur R, McCarron J, Rajeeve S, Mohyuddin GR (2024). The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization? Leuk Lymphoma, 1-3. ()
    4. Zhukovsky S, Cliff ERS, Mohyuddin GR (2024). Should we screen for plasma cell dyscrasias in people with low bone density? Lancet Haematol, 11(10), e715-e717. ()
    5. Kakkilaya A, Trando A, Cliff ERS, Mian H, Al Hadidi S, Aziz M, Goodman AM, Jeong AR, Smith WL, Kelkar AH, Russler-Germain DA, Mehra N, Chakraborty R, Gertz MA, Mohyuddin GR (2024). Evaluating early intervention in smoldering myeloma clinical trials: a systematic review. Oncologist. ()
    6. Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov D (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leuk Lymphoma, 65(9), 1-4. ()
    7. Mohyuddin GR, Goodman AM (2024). Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials. Nat Rev Clin Oncol. ()
    8. Mellgard G, Gilligan M, Cliff ERS, Bhutani D, Mohyuddin GR, Eisenberger A, Lentzsch S, Chakraborty R (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. Hemasphere, 8(3), e61. ()
    9. Ilerhunmwuwa NP, Abdul Khader AHS, Smith C, Cliff ERS, Booth CM, Rd EH, Aziz M, Lee-Smith W, Goodman A, Chakraborty R, Mohyuddin GR (2024). Dietary interventions in cancer: a systematic review of all randomized controlled trials. J Natl Cancer Inst. ()
    10. Mian H, Seow H, Pond GR, Gayowsky A, Foley R, Balistky A, Ebraheem M, Cipkar C, Sapru H, Mohyuddin GR, Hadidi SA, Visram A (2024). Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Clin Lymphoma Myeloma Leuk. ()
    11. Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin GR (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J, 14(1), 20. ()
    12. Balaban N, Mohyuddin GR, Kashi A, Massarweh A, Markel G, Bomze D, Goldstein DA, Meirson T (2023). Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. BMJ, 383, e077329. ()
    13. Abusamak AA, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Cliff ERS, Al Hadidi S (2023). Use of subjective minimizing language at hematology and oncology conferences: A systematic review. J Cancer Policy, 39, 100461. ()
    14. Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin GR (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Netw Open, 6(11), e2342195. ()
    15. Alrawabdeh J, Alzubi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Cliff ERS, Al Hadidi S (2023). Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review. JNCI Cancer Spectr, 7(6). ()
    16. Mohyuddin GR, Chakraborty R, Cliff ERS, Derman BA (2023). Clinician preferences on treatment of smoldering myeloma: aĀ cross-sectional survey. EClinicalMedicine, 65, 102272. ()
    17. Mohyuddin GR, Prasad V (2023). Detecting Selection Bias in Observational Studies-When Interventions Work Too Fast. JAMA Intern Med, 183(9), 897-898. ()
    18. Hentzen S, Meirson T, Koehn K, Goodman A, Chakraborty R, Sborov D, Rubinstein S, Mohyuddin GR (2023). Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review. Eur J Haematol, 111(3), 491-498. ()
    19. Booth CM, Sengar M, Goodman A, Wilson B, Aggarwal A, Berry S, Collingridge D, Denburg A, Eisenhauer EA, Ginsburg O, Goldstein D, Gunasekera S, Hammad N, Honda K, Jackson C, Karikios D, Knopf K, Koven R, Marini BL, Maskens D, Moraes FY, Mohyuddin GR, Poudyal BS, Pramesh CS, Roitberg F, Rubagumya F, Schott S, Sirohi B, Soto-Perez-de-Celis E, Sullivan R, Tannock IF, Trapani D, Tregear M, van der Graaf W, Vanderpuye V, Gyawali B (2023). Common Sense Oncology: outcomes that matter. Lancet Oncol, 24(8), 833-835. ()
    20. Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty R (2023). Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leuk Res, 131. ()
    21. Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty R (2023). Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leuk Res, 131, 107324. ()
    22. Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Ng Liet Hing M, Harrison SJ, Kesselheim A, Teh BW (2023). Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. ()
    23. McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, Kaedbey R, DSouza A, Mohyuddin GR, Wildes TM, Fonseca R, Mian H (2023). Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. ()
    24. Sengar M, Hopman WM, Mohyuddin GR, Goodman AM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM (2023). Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience, 17, 1558. ()
    25. Abdallah AO, Mahmoudjafari Z, Ahmed N, Cui W, Shune L, McGuirk J, Mohan M, Mohyuddin GR, Afrough A, Alkharabsheh O, Atrash S (2023). Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma. Eur J Haematol, 110(6), 626-632. ()
    26. Sharma N, Wayant C, Neupane K, Lenka J, Berger K, Goodman AM, Booth CM, Prasad V, Mohyuddin GR (2023). Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology. J Cancer Policy, 36, 100411. ()
    27. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leuk Lymphoma, 1-4. ()
    28. Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt A (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. Clin Hematol Int. ()
    29. Sawalha L, Kelkar AH, Mohyuddin GR, Goodman AM, Gagelmann N, Al Hadidi S (2023). Analysis of repeated roles in editorial boards at oncology focused journals. J Cancer Policy, 35. ()
    30. Mohyuddin GR, Chakraborty R, SchefferCliff ER (2023). The promise and harms of screening for plasma cell dyscrasias. Br J Haematol. ()
    31. Mohyuddin GR, Meirson T (2023). A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise. Nat Rev Clin Oncol. ()
    32. Sengar M, Hopman WM, Mohyuddin GR, Goodman AM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth CM (2023). Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience, 17. ()
    33. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48. ()
    34. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin GR (2022). Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. ()
    35. Mohyuddin GR, Sinnarajah A, Gayowsky A, Chan KKW, Seow H, Mian H (2022). Quality of end-of-life care in multiple myeloma: A 13-year analysis of a population-based cohort in Ontario, Canada. Br J Haematol, 199(5), 688-695. ()
    36. Atieh T, Atrash S, Ahmed N, Mohan M, Cui W, Shune L, Hajjar S, Mahmoudjafari Z, Quick J, Wishna A, Riffel J, McGuirk J, Mohyuddin GR, Abdallah AO (2022). Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 22(12), 912-919. ()
    37. Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov D (2022). A survey on the patient perspective on cure in multiple myeloma. Lancet Haematol, 9(10), e716-e719. ()
    38. Cliff ERS, Mohyuddin GR (2022). Overall survival as a primary end point in multiple myeloma trials. Nat Rev Clin Oncol, 19(9), 565-566. ()
    39. Mohyuddin GR, Mehra N, Ryll B, Prasad V (2022). Control participants of randomised trials: an often forgotten, vulnerable population. Lancet Haematol, 9(9), e634-e636. ()
    40. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin GR (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. Eur J Haematol, 109(5), 559-565. ()
    41. Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin GR (2022). Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol, 8, e2200119. ()
    42. Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clin Hematol Int, 4(1-2), 56-59. ()
    43. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin GR (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. Eur J Cancer, 167, 152-160. ()
    44. Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR (2022). Financial toxicity in hematological malignancies: a systematic review. Blood Cancer J, 12(4), 74. ()
    45. Berger K, Mohyuddin GR (2022). Reporting of trials with possible detrimental overall survival: a patient advocate perspective. Lancet Haematol, 9(2), e94. ()
    46. Mohyuddin GR, Mian H (2021). Daratumumab in newly diagnosed MM - incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nat Rev Clin Oncol, 19(1), 3-4. ()
    47. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. Eur J Cancer, 156, 164-174. ()
    48. Abdallah AO, Mohyuddin GR, Ahmed N, Mohan M, Cui W, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly S, Atrash S (2021). Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. EJHaem, 2(4), 757-764. ()
    49. Mohyuddin GR, Banerjee R, Alam Z, Berger KE, Chakraborty R (2021). Rethinking mechanisms of neurotoxicity with BCMA directed therapy .Crit Rev Oncol Hematol. 2021 Aug 27:103453. doi: 10.1016/j.critrevonc.2021.103453. Online ahead of print.PMID: 34461271 Review. Online prior to print. (2021.103453).
    50. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad V (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. 156(October 2021), 164-174.
    51. Pennipede D, Mohyuddin GR, Hawkins R, Ganguly S, Shune L, Ahmed N, Mohan M, Cui W, Mahmoudjafari Z, McGuirk J, Atrash S, Abdallah AO (2021). Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-class Relapsed/Refractory Multiple Myeloma (RRMM). Eur J Haematol. ()
    52. Mohyuddin GR, Hampton J, Aziz M, Khuder S, Malik S, McClune B, Abdallah AO (2021). A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 21(7), 489-496. ()
    53. Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J, Mohyuddin GR (2021). Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer, 21(1), 730. ()
    54. Ferguson JE, Vetos D, Ho BV, Aziz M, Lee WM, Mohyuddin GR, Prouty M (2021). Trends in diversity of participants in dermatology clinical trials over time: A systematic review. J Am Acad Dermatol. ()
    55. Mohyuddin GR, Koehn K, Shune L, Aziz M, Abdallah AO, McClune B, Ganguly S, McGuirk J, Kambhampati S (2021). Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 62(6), 1386-1395. ()
    56. Mohyuddin GR, Koehn K, Abdallah AO, W Sborov D, Rajkumar SV, Kumar S, McClune B (2021). Use of endpoints in multiple myeloma randomized controlled trials over the last 15ā€‰years: A systematic review. Am J Hematol, 96(6), 690-697. ()
    57. Mohyuddin GR, Abdallah AO, McClune B (2021). Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma. JAMA Oncol, 7(4), 635. ()
    58. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad V (2020). Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. Lancet Haematol, 8(4), e299-e304. ()
    59. Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad V (2021). Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review. JAMA Netw Open, 4(4), e218084. ()
    60. Abbasi S, Roller J, Abdallah AO, Shune L, McClune B, Sborov D, Mohyuddin GR (2021). Hospitalization at the end of life in patients with multiple myeloma. BMC Cancer, 21(1), 339. ()
    61. Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar SK (2020). Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood Adv, 5(4), 1097-1101. ()
    62. Mohyuddin GR, Lester K, Thomas L, Eck LM, Newman JR (2021). Implementation of an Audience Response System in a Case Conference Curriculum: Results of a Placebo-Controlled Trial. Cureus, 13(2), e13512. ()
    63. Abdallah AO, Mohyuddin GR, Mahmoudjafari Z, Atrash S, Kawsar H, Sigle M, Shune L, McGuirk J, Ganguly S (2020). Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 21(2), e212-e219. ()
    64. Abdallah AO, Sigle M, Mohyuddin GR, Coggins E, Remker C, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly S (2020). Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk, 21(2), e220-e226. ()
    65. Gaudel P, Mohyuddin GR, Fields-Meehan J (2021). Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. Fed Pract, 38(2), 89-91. ()
    66. Mohyuddin GR, Abbasi S, Okoniewski M, McClune B, Abdallah AO, Ganguly S, McGuirk J, Shune L (2020). Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation. Eur J Haematol, 105(5), 571-577. ()
    67. Mohyuddin GR, Koehn K, Costa L, Kumar SK, McClune B (2020). Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. Lancet Haematol, 7(10), e704-e706. ()
    68. Dominick A, Mohyuddin GR, Fields-Meehan J, Mathur S (2020). Combination Immunotherapy Associated With Severe Hepatotoxicity and Fatal Aplastic Anemia. Am J Ther. ()
    69. Britt A, Mohyuddin GR, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, Godwin A, Pessetto Z, Golem S, Divine C, Dias A (2020). Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res, 95, 106402. ()
    70. Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A (2020). Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC Cancer, 20(1), 507. ()
    71. Britt A, Mohyuddin GR, Al-Rajabi R (2020). Maintenance of Stable Disease in Metastatic Perivascular Epithelioid Cell Tumor of the Liver With Single-Agent Sorafenib. Am J Ther. ()
    72. Mohyuddin GR, Dominick A, Black T, Hoffman M, Male H, Byrd K, McClune B, Eck L, Neupane P (2020). A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency. J Cancer Educ. ()
    73. Mohyuddin GR, Aziz M, McClune B, Abdallah AO, Qazilbash M (2020). Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. Eur J Haematol, 104(5), 420-426. ()
    74. Mohyuddin GR, Jobe A, Thomas L (2020). Does Use of High-fidelity Simulation Improve Resident Physician Competency and Comfort Identifying and Managing Bradyarrhythmias? Cureus, 12(2), e6872. ()
    75. Al-Kofahi M, Mohyuddin GR, Taylor ME, Eck LM (2019). Reducing Resident Physician Workload to Improve Well Being. Cureus, 11(6), e5039. ()
    76. Mohyuddin GR, Romanelli N, Shune L, Abhyankar S, Ganguly S, McGuirk J, Singh A (2018). Autologous hematopoietic stem cell transplant is safe for elderly lymphoma patients. Hematol Oncol Stem Cell Ther, 12(2), 124-125. ()
    77. Mohyuddin GR, Isom N, Thomas L (2019). Applying the Principles of Bloom's Taxonomy to Managing Tachyarrhythmia: Results of a Tachyarrhythmia Workshop. Cureus, 11(2), e4037. ()
    78. Mohyuddin GR, Qazilbash M (2018). The role of NK Cells in Multiple Myeloma.
    79. Mohyuddin GR, Clark AE, Roller J, Shune L, Lin T, Dunavin N, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh A (2017). Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. Hematol Oncol Stem Cell Ther, 11(3), 135-141. ()
    80. Mohyuddin GR, Clark AE, Roller J, Shune L, Lin T, Dunavin N, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh A (2018). Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. Acta Haematol, 139(1), 52-57. ()
    81. Mohyuddin GR, Uy J, Medhavi H, Faisal MS, Qazilbash MH (2017). Immune-Mediated Neuropathies following Autologous Stem Cell Transplantation for Multiple Myeloma: Case Series and Review of the Literature. Acta Haematol, 137(2), 86-88. ()
    82. Parkash O, Mohyuddin GR, Ayub A, Nazir I, Maan AA, Hamid S (2017). Electrophysiological changes in patients with liver cirrhosis in a tertiary care hospital in Karachi, Pakistan. J Ayub Med Coll Abbottabad, 28(4), 676-679. ()
    83. Mohyuddin GR, Alam Z, Malik UZ, Shakil O, ul Haq A (2016). REVISED TRAUMA SCORE AS A PREDICTOR OF OUTCOME IN TRAUMA CASES: EXPERIENCES AT A TERTIARY CARE HOSPITAL IN KARACHI, PAKISTAN. J Ayub Med Coll Abbottabad, 27(3), 584-6. ()
    84. Mohyuddin GR, Al Asad M, Scratchko L, Khaleeq G (2013). Acute generalized exanthematous pustulosis with multiple organ dysfunction syndrome. Am J Crit Care, 22(3), 270-3. ()
    85. Mohyuddin GR, Rabinowitz I (2013). A patient with chronic lymphocytic leukemia and acquired angioedema: Correlation of clinical and biochemical response to CLL therapy. Ecancermedicalscience, 7(1). ()
    86. Khan C, Mohyuddin GR (2013). Bone Marrow Biopsy Simulation Training for Fellows. 4(4).
    87. Mohyuddin GR, Qureshi R (2012). Recommendation for use of Vitamin ‘D’ Treatment during Pregnancy. 4, 223-6.

    Review

    1. Vaquera-Alfaro HA, Gmez-De Len A, Desai N, Mehra N, Mohyuddin GR (2024). Transplant in myeloma: individualized approaches needed depending on context, access and biology. [Review]. Bone Marrow Transplant. ()
    2. Zhukovsky S, White J, Chakraborty R, Costa LJ, Van Oekelen O, Sborov DW, Cliff ERS, Mohyuddin GR (2024). Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria. [Review]. Leuk Lymphoma, 1-10. ()
    3. Beechinor RJ, Mohyuddin GR, Mitchell DE, Aaron D, Mahmoudjafari Z (2023). The story of the development of generic lenalidomide: How one company thwarted the Hatch-Waxman Act to generate billions of dollars in revenue. [Review]. J Cancer Policy, 38, 100446. ()
    4. Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin GR (2023). Multiple Myeloma in Young Patients: A Scoping Review. [Review]. Clin Lymphoma Myeloma Leuk, 24(1), 15-22. ()
    5. Ouchveridze E, Berger K, Mohyuddin GR (2022). Value in Myeloma Care: Myth or Reality. [Review]. Curr Hematol Malig Rep, 17, 206-216. ()
    6. Wayant C, Mohyuddin GR, Prasad V (2022). The accelerated approval pathway in oncology: Balancing the benefits and potential harms. [Review]. J Cancer Policy, 32, 100323. ()
    7. Mohyuddin GR, Banerjee R, Alam Z, Berger KE, Chakraborty R (2021). Rethinking mechanisms of neurotoxicity with BCMA directed therapy. [Review]. Crit Rev Oncol Hematol, 166, 103453. ()

    Case Report

    1. Yacoub A, Mohyuddin GR, Nazzaro JM (2019). Bilateral subthalmic nucleus deep brain stimulation with microelectrode recordings in the setting of mild inherited hemophilia B: a case report. Int J Neurosci, 129(9), 933-935. ()
    2. Jobe AL, Ahonen KT, Poplin V, Rao S, Mohyuddin GR (2018). Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature. Cureus, 10(6), e2805. ()
    3. Mohyuddin GR, Yacoub A (2016). Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature. Case Rep Hematol, 2016, 9515404. ()
    4. Mohyuddin GR, Male HJ (2016). A Rare Cause of Hemophagocytic Lymphohistiocytosis: Fusobacterium Infection-A Case Report and Review of the Literature. Case Rep Hematol, 2016, 4839146. ()
    5. Mohyuddin GR, Sultan F, Zhang K, Khaleeq G (2013). Sulfasalazine induced lung toxicity masquerading as sarcoidosis--case report and review of the literature. Sarcoidosis Vasc Diffuse Lung Dis, 30(3), 226-30. ()
    6. Moosajee SM, Mohyuddin GR, Khan S, Kamal AK (2013). Acute acquired demyelinating polyneuropathy–an initial presentation of diffuse large B cell lymphoma. 4(1), 35-8.
    7. Mohyuddin G, Rabinowitz I (2013). A patient with chronic lymphocytic leukemia and acquired angioedema: correlation of clinical and biochemical response to CLL therapy. Ecancermedicalscience, 7, 292. ()
    8. Mohyuddin GR, Sultan F, Khaleeq G (2012). A rare presentation of a rare disease: pulmonary lymphomatoid granulomatosis. Case Rep Pulmonol, 2012, 371490. ()

    Editorial

    1. Smith C, Booth CM, Mohyuddin GR (2024). Dietary interventions, statistical power, and unanswered questions. J Natl Cancer Inst, 116(8), 1404-1405. ()
    2. Mohyuddin GR, Banerjee R, Goodman AM (2021). Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concern. Eur J Cancer, 157, 533-535. ()

    Letter

    1. Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, DSouza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan M (2024). Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. [Letter to the editor]. Blood Cancer J, 14(1), 137. ()
    2. Mohyuddin GR, Rubinstein SM, Kumar S, Rajkumar SV, Fonseca R, Abdallah NH, Calip GS, Wang X, Parrinello CM, Sborov D (2024). Performance of newer myeloma staging systems in a contemporary, large patient cohort. [Letter to the editor]. Blood Cancer J, 14(1), 95. ()
    3. Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Rasche L, Schinke C, DSouza A, Mohan M (2024). Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. [Letter to the editor]. Blood Cancer J, 14(1), 36. ()
    4. Chakraborty R, Hadidi SA, Scheffer Cliff ER, Mohyuddin GR (2023). Is aggressive treatment of smoldering myeloma the path to curing myeloma? [Letter to the editor]. Blood Adv, 7(15), 3932-3935. ()
    5. Beechinor RJ, Mahmoudjafari Z, Mohyuddin GR (2023). Financial Toxicity in Oncology, More Unanswered Questions. [Letter to the editor]. J Clin Oncol, JCO2300915. ()
    6. Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt A (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma [Letter to the editor]. Clin Hematol Int, 5(2-3), 170-176. ()
    7. Mohyuddin GR, Goodman AM (2023). Ineligible for transplant, but eligible for intensive quadruplet therapy-The value of 'add-on' trials for vulnerable patient populations. [Letter to the editor]. Eur J Cancer, 185, 164-166. ()
    8. Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin GR (2023). Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma. [Letter to the editor]. J Clin Oncol, 41(10), 1949-1951. ()
    9. Mohyuddin GR, Kapur R, Costa L (2023). Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy? [Letter to the editor]. Br J Haematol. ()
    10. Ouchveridze E, Booth C, Mohyuddin GR (2023). Subgroups and precision in myeloma [Letter to the editor]. J Cancer Policy, 35. ()
    11. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Jullian K, Wagner C, Mohyuddin GR (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials [Letter to the editor]. Leuk Lymphoma. ()
    12. Mohyuddin GR, Chakraborty R, Calip GS, Ascha MS, Wang X, Rubinstein SM, Tuchman S, Costa L, Haaland B, Giri S, Mian H, Fonseca R, Sborov D (2022). Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. [Letter to the editor]. Blood Cancer J, 12(12), 168. ()
    13. Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin GR (2022). Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020. [Letter to the editor]. Blood Cancer J, 12(11), 155. ()
    14. Cliff ERS, Mian H, Mohyuddin GR (2022). Teclistamab in Relapsed or Refractory Multiple Myeloma [Letter to the editor]. N Engl J Med, 387(18), 1721-1722. ()
    15. Goodman AM, Mohyuddin GR, Prasad V (2022). Ivosidenib and Azacitidine in IDH1-Mutated AML. [Letter to the editor]. N Engl J Med, 386(26), 2536. ()
    16. Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin GR (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma [Letter to the editor]. Clin Hematol Int, 4(1-2), 56-59. ()
    17. Soomro MA, Hoffman J, Goodman AM, Sborov DW, Mohyuddin GR (2022). Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials. [Letter to the editor]. Br J Haematol, 197(6), e86-e88. ()
    18. Banerjee R, Midha S, Kelkar AH, Goodman A, Prasad V, Mohyuddin GR (2021). Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. [Letter to the editor]. Br J Haematol, 196(5), 1274-1277. ()
    19. Meirson T, Markel G, Prasad V, Goodman AM, Mohyuddin GR (2022). Post-protocol therapy and informative censoring in the CANDOR study. [Letter to the editor]. Lancet Oncol, 23(3), e97. ()
    20. Mohyuddin GR, Goodman AM, Knopf K (2021). Perils of Ignoring Overall Survival in Interpreting the Myeloma Literature. [Letter to the editor]. J Clin Oncol, 40(1), 105-106. ()
    21. Mohyuddin GR, Ouchveridze E, Goodman A, Prasad V (2021). The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. [Letter to the editor]. Leuk Lymphoma, 1-3. ()
    22. Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V (2020). Multiple myeloma triplet therapies: baseline characteristics and control groups. [Letter to the editor]. Lancet, 397(10285), 1620-1621. ()
    23. Mohyuddin GR, Okoniewski M, Diab O, Ganguly S, Shune L, Abdallah AO, McGuirk J, McClune B (2020). Maintenance regimens after a second autologous transplant for multiple myeloma. [Letter to the editor]. Leuk Lymphoma, 62(3), 758-760. ()
    24. Ripp J, Mohyuddin GR, Al-Jumayli M, Huang C (2021). Outcomes in older patients with NSCLC receiving immunotherapy: A single center experience. [Letter to the editor]. J Geriatr Oncol. ()
    25. Mohyuddin GR, Abbasi S, Ripp J, Singh A, Kambhampati S, McClune B (2020). Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better. [Letter to the editor]. Leuk Lymphoma, 61(11), 2760-2762. ()
    26. Mohyuddin GR, Sigle M, Chandrasekar VT, Aziz M, Abdallah AO, Shune L, McClune B (2020). Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis. [Letter to the editor]. Leuk Lymphoma, 61(10), 2519-2522. ()
    27. Abbasi S, Britt A, McClune B, Shune L, Kambhampati S, Mohyuddin GR (2020). Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample. [Letter to the editor]. Leuk Lymphoma, 61(5), 1254-1256. ()
    28. Mohyuddin GR, Roller J, Shune L, Lin T, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh A (2018). Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. [Letter to the editor]. Hematol Oncol Stem Cell Ther, 12(3), 171-173. ()
    29. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH (2017). A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. [Letter to the editor]. Leuk Lymphoma, 59(2), 515-518. ()

  • Clinical Trials